Article
Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response
2023-08-18
Abstract excerpt
The advent of tyrosine kinase inhibitors (TKIs) as treatment of chronic myeloid leukemia (CML) is a paradigm in molecularly targeted cancer therapy. Nonetheless, TKI insensitive leukemia stem cells (LSCs) persist in most patients even after years of treatment. The sustained presence, heterogeneity and evolvability of LSCs are imperative for disease progression as well as recurrence during treatment-free remission...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1570bb5d-9697-5d77-98a4-2a87ed31daf4
- DOI
- 10.1101/2023.08.16.553504
